Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced that its Board of Directors resolved at a meeting held on February 28, 2022, to establish a holding company in China as a wholly owned subsidiary.
The Company decided to establish a holding company, "Sumitomo Pharma (China) Co., Ltd." in China as a wholly owned subsidiary to manage and enhance our China business.
Notice of Establishment of Holding Company in China
DSPC-NP-CI-22-03-0007
We use cookies to maintain the proper functioning of our website and to personalize and improve your experience. By clicking “Agree and visit the site” you accept all cookies. For more information, please visit our Privacy Policy.
You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.
